Vera Therapeutics, Inc. Class A Common Stock
VERA
$42.96
+7.05%
Vera Therapeutics is a clinical-stage biotechnology company focused on developing transformative treatments for serious immunological diseases, with its lead product candidate atacicept targeting autoimmune conditions like IgA nephropathy. As a pre-commercial biotech, it occupies a high-risk, high-reward niche in the biotech sector, with its pipeline centered on a single key asset. The current investor narrative is dominated by the upcoming July 7 FDA decision on atacicept, which has driven significant stock volatility and attention, as a positive outcome could transform the company into a commercial-stage entity.…
VERA
Vera Therapeutics, Inc. Class A Common Stock
$42.96
Related headlines
Investment Opinion: Should I buy VERA Today?
Rating: Speculative Buy — Vera Therapeutics offers a high-risk, high-reward opportunity driven by the upcoming FDA decision on atacicept. The analyst consensus is bullish (4 Buy ratings), but the lack of target prices limits the ability to quantify upside. The core thesis is that approval will transform Vera into a commercial-stage biotech with a blockbuster drug in a large market.
Supporting Evidence: The primary valuation metric is price-to-book at 5.38x, which is above the industry average of 3-4x but justified by the potential revenue opportunity (analyst average revenue estimate of $1.32 billion). The company has zero revenue currently, but if approved, revenue could ramp quickly. The strong cash position ($354.7 million) provides a cushion, and the recent $200 million fund investment signals institutional confidence. The stock's 1-year return of +74.2% vastly outperforms the S&P 500's +19.1%, reflecting the market's optimism. However, the lack of profitability (net loss of -$91.1 million in Q4) and negative free cash flow (-$241.7 million TTM) are significant concerns.
Risks & Conditions: The biggest risk is FDA non-approval, which would invalidate the entire thesis. This Hold would upgrade to a Strong Buy if the FDA approves atacicept with a favorable label, as the stock could re-rate higher. Conversely, a Sell rating would be warranted if the FDA issues a CRL or if clinical data shows safety/efficacy issues. The stock is currently overvalued relative to its pre-revenue status, but fairly valued if one assumes a high probability of approval. The valuation verdict is that the stock is a speculative buy for risk-tolerant investors willing to bet on the binary catalyst.
Sign up to view all
VERA 12-Month Price Forecast
The AI assessment is bullish with medium confidence, reflecting the high probability of FDA approval implied by recent price action and analyst sentiment. The key factors supporting this view are the strong cash position, unanimous Buy ratings, and the large market opportunity for atacicept. However, confidence is tempered by the binary nature of the catalyst and the elevated valuation (PB 5.38x) for a pre-revenue company. If the FDA approves atacicept, the stock could see significant upside toward the 52-week high and beyond. If denied, the downside is severe. The stance would be upgraded to high confidence if additional positive clinical data emerges before the decision, and downgraded to bearish if regulatory risks increase.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vera Therapeutics, Inc. Class A Common Stock's 12-month outlook, with a consensus price target around $55.85 and implied upside of +30.0% versus the current price.
Average Target
$55.85
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$34 - $56
Analyst target range
Analyst coverage is limited, with only 4 analysts providing estimates, which is typical for a small-cap biotech. The consensus recommendation is bullish, with recent ratings including Buy from HC Wainwright, Goldman Sachs, B of A Securities, and TD Cowen, and Outperform from Wolfe Research and Evercore ISI. The average estimated EPS for the next fiscal year is $7.03, with a low of $2.61 and a high of $16.98, implying a wide range of expectations. The average revenue estimate is $1.32 billion, with a low of $679 million and a high of $2.75 billion, reflecting the binary nature of the FDA decision. The implied upside or downside cannot be calculated without a target price, but the high EPS estimate suggests some analysts expect significant profitability post-approval. The wide range of estimates (high EPS is 6.5x the low) signals high uncertainty, which is typical for a binary event stock. The recent upgrade by Wolfe Research from Peer Perform to Outperform in March 2026 indicates growing optimism ahead of the July 7 FDA decision. The limited analyst coverage means the stock may be less efficiently priced, leading to higher volatility and potential mispricing opportunities.
Bulls vs Bears: VERA Investment Factors
Vera Therapeutics presents a high-risk, high-reward binary investment opportunity centered on the July 7 FDA decision for atacicept. The bull case is compelling: a strong cash position, massive market opportunity, and unanimous analyst Buy ratings suggest approval could drive significant upside. However, the bear case is equally potent: zero revenue, widening losses, and a single-pipeline dependency mean rejection could lead to a 50%+ decline. The most critical tension is the binary FDA outcome—approval could propel the stock to new highs, while denial would likely send it to or below the 52-week low. Currently, the evidence slightly favors the bulls given the recent price momentum and positive analyst sentiment, but the risk-reward is highly asymmetric and event-driven.
Bullish
- High-Probability FDA Approval Catalyst: The July 7 FDA decision on atacicept for IgA nephropathy is a binary catalyst that could transform Vera from a clinical-stage biotech into a commercial entity. A $200 million fund bet and recent analyst upgrades (Wolfe Research to Outperform) signal growing confidence in approval, with the stock surging 31.8% in the past month alone.
- Strong Cash Position Mitigates Dilution Risk: Vera holds $354.7 million in cash as of Q4 2025, up from $92.6 million a year earlier, following a $286.3 million equity offering. With a current ratio of 13.6 and debt-to-equity of only 0.13, the company has ample runway to fund operations through the FDA decision and potential launch without near-term financing risk.
- Massive Market Opportunity in IgA Nephropathy: Analyst revenue estimates for the next fiscal year average $1.32 billion, with a high estimate of $2.75 billion, reflecting the large addressable market for atacicept. If approved, atacicept could become a standard-of-care treatment, driving significant top-line growth from zero revenue base.
- Positive Analyst Sentiment and Limited Coverage: All four covering analysts rate the stock a Buy, with recent upgrades and no sell ratings. The limited coverage (4 analysts) suggests the stock may be underfollowed, creating potential for positive surprises and multiple expansion as more analysts initiate coverage post-approval.
Bearish
- Binary FDA Risk with No Revenue Backstop: Vera has zero revenue and is entirely dependent on atacicept approval. If the FDA rejects or delays the drug, the stock could collapse, as there is no approved product or pipeline diversification to fall back on. The 52-week low of $19.07 represents a potential 54% downside from the current price of $41.20.
- Widening Losses and Cash Burn: Net loss in Q4 2025 was -$91.1 million, more than double the -$43.4 million loss in Q4 2024, driven by rising R&D and SG&A costs. Free cash flow was -$70.1 million in Q4, and trailing twelve-month FCF is -$241.7 million, indicating accelerating cash burn that could necessitate future dilution if approval is delayed.
- Elevated Valuation for Pre-Revenue Biotech: The price-to-book ratio of 5.38x is above the industry average of 3-4x for pre-commercial biotechs, implying the market is pricing in a high probability of approval and significant commercial success. Any negative news on efficacy, safety, or commercial uptake could lead to multiple compression.
- High Short Interest and Volatility Risk: The short ratio is 10.98 days to cover, indicating significant bearish positioning. This creates potential for a short squeeze on positive news, but also reflects skepticism about the approval timeline or commercial potential. The stock's beta of 0.92 is low for a small-cap biotech, but idiosyncratic volatility remains high.
VERA Technical Analysis
The stock is in a volatile uptrend over the past year, with a 1-year price change of +74.2%, significantly outperforming the S&P 500's +19.1%. Currently trading at $41.20, it sits at 58.8% of its 52-week range ($19.07 to $56.05), suggesting it is in the middle of the range after a sharp recovery from recent lows. This positioning indicates a stock that has experienced strong momentum but is not yet overextended near its highs, leaving room for further upside if catalysts materialize. Short-term momentum shows a sharp divergence: the 1-month change is +31.8%, while the 3-month change is only +0.8%, and the 6-month change is -15.3%. This pattern suggests a powerful short-term rally that has reversed a multi-month downtrend, potentially signaling a trend reversal or a mean-reversion bounce. The relative strength versus the S&P 500 is strongly positive over 1 month (+33.0%) but negative over 3 months (-12.7%), indicating that the recent rally is company-specific rather than market-driven. Key support lies near the 52-week low of $19.07, while resistance is at the 52-week high of $56.05. A breakout above $56.05 would signal a resumption of the long-term uptrend, while a breakdown below $19.07 would indicate a bearish collapse. The stock's beta of 0.92 suggests slightly lower volatility than the market, which is unusual for a small-cap biotech, implying that recent price swings are driven by idiosyncratic events rather than broad market moves.
Beta
0.92
0.92x market volatility
Max Drawdown
-43.9%
Largest decline past year
52-Week Range
$19-$56
Price range past year
Annual Return
+87.0%
Cumulative gain past year
| Period | VERA Return | S&P 500 |
|---|---|---|
| 1m | +33.0% | +1.4% |
| 3m | +6.5% | +10.6% |
| 6m | -9.9% | +8.4% |
| 1y | +87.0% | +20.5% |
| ytd | -11.6% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VERA Fundamental Analysis
Vera Therapeutics is a pre-revenue clinical-stage biotech, with zero revenue reported in the most recent quarter (Q4 2025) and no revenue in any of the last eight quarters. The company's growth trajectory is entirely dependent on the success of atacicept; there are no approved products generating sales. The lack of revenue means the investment case hinges on binary FDA approval, making traditional growth analysis inapplicable. The company is deeply unprofitable, with a net loss of -$91.1 million in Q4 2025, widening from -$43.4 million in Q4 2024. Gross margin is zero due to no revenue, and operating expenses (R&D and SG&A) totaled $95.3 million in Q4 2025, up from $48.9 million a year earlier, reflecting increased clinical trial and regulatory preparation costs. The net loss per share was -$1.39 in Q4 2025, compared to -$0.85 in Q4 2024, indicating deteriorating profitability as the company scales up for potential commercialization. The balance sheet shows a strong cash position of $354.7 million as of Q4 2025, up from $92.6 million a year earlier, following a $286.3 million equity offering. The debt-to-equity ratio is low at 0.13, and the current ratio is 13.6, indicating ample liquidity. However, free cash flow was -$70.1 million in Q4 2025, and the trailing twelve-month free cash flow is -$241.7 million, meaning the company is burning cash rapidly. The ROE is -49.6%, reflecting significant shareholder dilution and losses. The company's ability to fund operations without additional financing depends on the FDA outcome; if approved, cash burn may decrease as revenue begins, but if not, further dilution or partnership deals will be needed.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-241734000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VERA Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is not applicable (revenue is zero). Instead, we use the price-to-book (PB) ratio as the primary valuation metric, as the company has positive book value. The trailing PB ratio is 5.38x, which is elevated for a pre-revenue biotech, reflecting the market's expectation of future cash flows from atacicept. The forward PE is -10.84x, but this is meaningless due to negative earnings. The PB ratio of 5.38x is above the industry average for biotechnology, which typically trades around 3-4x book value for pre-commercial firms. This premium suggests the market is pricing in a high probability of FDA approval and significant commercial success. However, the premium is justified by the company's strong cash position and the potential of atacicept in a large market (IgA nephropathy). Historically, the PB ratio has ranged from 1.51x (Q2 2021) to 8.39x (Q3 2024), with the current 5.38x near the middle of that range. This suggests the stock is not at extreme valuation levels relative to its own history, but it is above the median of around 4.5x, indicating that the market is optimistic but not euphoric. The PB ratio has been volatile, reflecting the binary nature of the stock.
PE
-10.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -19x~-2x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-10.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Vera's financial profile is typical of a pre-revenue biotech but with accelerating losses. Net loss widened to -$91.1 million in Q4 2025 from -$43.4 million a year ago, and free cash flow was -$70.1 million in the quarter. The company has $354.7 million in cash, but at the current burn rate of ~$240 million annually, it has roughly 1.5 years of runway without additional financing. If the FDA decision is delayed or negative, Vera may need to raise capital through dilutive equity offerings or partnerships, which could pressure the stock. The ROE of -49.6% reflects significant shareholder dilution and negative returns on equity, underscoring the high financial risk of investing in a pre-commercial stage company.
Market & Competitive Risks: Vera's valuation is elevated relative to peers, with a PB ratio of 5.38x versus the industry average of 3-4x for pre-commercial biotechs. This premium implies the market is pricing in a high probability of FDA approval and substantial commercial success. If atacicept faces competition from other IgA nephropathy treatments (e.g., from Calliditas or Novartis), or if the FDA requires additional trials, the stock could de-rate significantly. The stock's beta of 0.92 suggests lower market correlation than typical small-cap biotechs, but idiosyncratic risk is high due to the binary catalyst. Recent news of a $200 million fund bet highlights institutional interest, but also raises the risk of a crowded trade that could unwind quickly on negative news.
Worst-Case Scenario: The most damaging scenario is an FDA rejection or Complete Response Letter (CRL) for atacicept on July 7. In this case, the stock would likely gap down sharply, potentially testing the 52-week low of $19.07, representing a 54% decline from the current price of $41.20. Without a pipeline backup, Vera would need to either conduct additional trials (delaying approval by years) or seek a partnership on unfavorable terms. The historical max drawdown of -43.85% suggests that severe declines are possible, and a rejection could exceed that, given the binary nature of the catalyst. Investors could lose more than half their investment in this adverse scenario.
FAQ
The primary risk is FDA non-approval of atacicept on July 7, which would likely cause the stock to collapse toward the 52-week low of $19.07. Financial risks include widening losses (net loss of -$91.1 million in Q4 2025) and cash burn of -$241.7 million TTM, which could necessitate dilutive financing if approval is delayed. Competitive risks include other IgA nephropathy treatments from companies like Calliditas or Novartis that could limit atacicept's market share. Additionally, the stock's high short ratio of 10.98 days to cover indicates significant bearish sentiment, which could amplify downside on negative news.
The 12-month forecast is highly dependent on the July 7 FDA decision. In the bull case (40% probability), approval drives the stock to $56-$70, with catalysts including a broad label and strong commercial uptake. The base case (35% probability) sees approval with restrictions, keeping the stock in a $40-$56 range as the market assesses sales trajectory. The bear case (25% probability) involves FDA rejection, sending the stock to $19-$30. The most likely scenario is the bull case, given the recent positive momentum and analyst sentiment, but the binary nature means outcomes are extreme. Investors should monitor the FDA decision as the key determinant.
VERA's valuation is elevated for a pre-revenue biotech, with a price-to-book ratio of 5.38x versus the industry average of 3-4x. This premium reflects the market's expectation of FDA approval and significant commercial success. The stock is overvalued relative to its current financials (zero revenue, negative earnings), but could be considered undervalued if atacicept achieves the analyst average revenue estimate of $1.32 billion. The PB ratio is near the middle of its historical range (1.51x to 8.39x), suggesting the market is optimistic but not euphoric. Ultimately, the valuation is justified only if the FDA approves atacicept and the drug generates substantial sales.
VERA is a speculative buy for risk-tolerant investors willing to bet on the July 7 FDA approval of atacicept. The stock has strong momentum (up 31.8% in the past month) and unanimous analyst Buy ratings, but it carries extreme binary risk. If approved, the stock could rally above the 52-week high of $56.05, offering significant upside. However, if rejected, the stock could fall to the 52-week low of $19.07, a 54% decline. The risk-reward is asymmetric but heavily dependent on the FDA decision. It is not a good buy for conservative investors or those unable to tolerate a potential total loss of capital.
VERA is best suited for short-term, event-driven trading focused on the July 7 FDA decision. The stock's extreme volatility (beta 0.92 but high idiosyncratic risk) and binary catalyst make it unsuitable for long-term holding without a clear view on approval. If atacicept is approved, the stock could become a long-term growth holding as revenue ramps, but the initial post-approval period may still be volatile. For risk-tolerant investors, a short-term hold through the FDA decision with a stop-loss is appropriate. Long-term investors should wait for approval and assess commercial execution before committing. The stock pays no dividend and has negative earnings, so it is not an income or value investment.